Eli Lilly: Baricitinib, Remdesivir reduce COVID-19 hospitalization
Monday, September 14, 2020 - 13:11
in Health & Medicine
Drugmaker Eli Lilly and Incyte said Monday Baricitinib in combination with Remdesivir met the primary endpoint of reduction of time to recovery in comparison with just Remdesivir in a COVID-19 treatment trial.